紫杉烷通过减弱CXCR2/BCL-2轴使前列腺癌对铂类治疗敏感
本研究分析公共mCRPC转录组数据,并在紫杉烷耐药细胞系和基因工程小鼠模型中验证,发现紫杉烷暴露后CXCR2和BCL-2下调,使前列腺癌细胞对顺铂敏感,紫杉烷-铂类联合在体内高度协同。
要点
- 紫杉烷暴露后mCRPC肿瘤中CXCR2和BCL-2表达下调
- CXCR2/BCL-2轴减弱是铂类治疗的获得性脆弱性
- 既往紫杉烷暴露使mCRPC对二线顺铂敏感
核心结论
- 紫杉烷治疗导致mCRPC中CXCR2/BCL-2轴减弱,该获得性脆弱性可能预测铂类治疗反应。
研究设计与样本
- 分析公共mCRPC转录组数据(紫杉烷暴露与未暴露患者),并在紫杉烷耐药mCRPC细胞系和基因工程小鼠模型中进行功能和临床前验证。
主要发现
- 紫杉烷暴露的人mCRPC肿瘤转录组显示凋亡和炎症反应通路显著负富集,伴CXCR2和BCL-2显著下调。
- 多西他赛抑制CXCR2,BCL-2下调为其下游效应。
- 实验模型中顺铂敏感性依赖CXCR2和BCL-2,靶向二者使前列腺癌细胞对顺铂敏感。
- 体内紫杉烷-铂类联合高度协同,既往紫杉烷暴露使mCRPC肿瘤对二线顺铂治疗敏感。
临床怎么用
- 对于mCRPC患者,紫杉烷暴露后CXCR2/BCL-2轴下调可能作为铂类治疗的预测指标。
- 紫杉烷-铂类联合化疗在部分患者中具有协同抗肿瘤作用。
局限性
- 转录组分析基于公共数据集,临床前验证使用细胞系和动物模型,尚未在临床队列中验证预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown clinical benefit in a subset of patients, but the mechanistic basis and biomarkers remain elusive. OBJECTIVE: To identify mechanisms and response indicators for the antitumor efficacy of taxane-platinum combinations in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Transcriptomic data from a publicly available mCRPC dataset of taxane-exposed and taxane-naïve patients were analyzed to identify response indicators and emerging vulnerabilities. Functional and preclinical validation was performed in taxane-resistant mCRPC cell lines and genetically engineered mouse models (GEMMs). INTERVENTION: Metastatic CRPC cells were treated with docetaxel, cisplatin, carboplatin, the CXCR2 antagonist SB265610, and the BCL-2 inhibitor venetoclax. Gain and loss of function in culture of CXCR2 and BCL-2 were achieved by overexpression or siRNA silencing. Preclinical assays in GEMM mice tested the antitumor efficacy of taxane-platinum combinations. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Proliferation, apoptosis, and colony assays measured drug activity in vitro. Preclinical endpoints in mice included growth, survival, and histopathology. Changes in CXCR2, BCL-2, and chemokines were analyzed by reverse transcriptase quantitative polymerase chain reaction and Western blot. Human expression data were analyzed using Gene Set Enrichment Analysis, hierarchical clustering, and correlation studies. GraphPad Prism software and R-studio were used for statistical and data analyses. RESULTS AND LIMITATIONS: Transcriptomic data from taxane-exposed human mCRPC tumors correlate with a marked negative enrichment of apoptosis and inflammatory response pathways accompanied by a marked downregulation of CXCR2 and BCL-2. Mechanistically, we show that docetaxel inhibits CXCR2 and that BCL-2 downregulation occurs as a downstream effect. Further, we demonstrated in experimental models that the sensitivity to cisplatin is dependent on CXCR2 and BCL-2, and that targeting them sensitizes prostate cancer (PC) cells to cisplatin. In vivo taxane-platinum combinations are highly synergistic, and previous exposure to taxanes sensitizes mCRPC tumors to second-line cisplatin treatment. CONCLUSIONS: The hitherto unappreciated attenuation of the CXCR2/BCL-2 axis in taxane-treated mCRPC patients is an acquired vulnerability with potential predictive activity for platinum-based treatments. PATIENT SUMMARY: A subset of patients with aggressive and therapy-resistant prostate cancer benefits from taxane-platinum combination chemotherapy; however, we lack the mechanistic understanding of how that synergistic effect occurs. Here, using patient data and preclinical models, we found that taxanes reduce cancer cell escape mechanisms to chemotherapy-induced cell death, hence making these cells more vulnerable to additional platinum treatment.
引用
- Ruiz de Porras V, Wang XC, Palomero L, et al. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol. 2020. PMID: 33153817. doi:10.1016/j.eururo.2020.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。